Pressemitteilung BoxID: 696475 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • Ansprechpartner
  • Chad Rubin
  • +1 (646) 378-2947

4SC AG: Dr Thomas Werner and Klaus Kühn announce resignation from Supervisory Board

(PresseBox) (Martinsried, ) 4SC AG (Frankfurt, Prime Standard: VSC) announces that Dr Thomas Werner and Klaus Kühn have informed the company today that they will resign from their positions as members of the Supervisory Board of 4SC AG for personal reasons effective at the end of 18 September 2014. Dr Werner has been a member of 4SC's Supervisory Board since June 2009, serving as its Chairman since June 2012; Mr Kühn has been a member of the Supervisory Board since August 2012.

The remaining Supervisory Board consisting of four members remains fully quorate. 4SC will provide timely information about how the vacant positions will be filled.

The Management Board of 4SC AG thanks Dr Werner and Mr Kühn for their commendable service and their strong dedication to the company.

Additional information of the issuer of this release

Enno Spillner, Chief Executive Officer of 4SC AG, comments: "On behalf of the 4SC Management Board, I wish to thank Dr Werner and Mr Kühn for their great dedication to 4SC and for their collaboration in the past years, which was always fair, positive and constructive. We regret their departure very much. We will now work with our full dedication to promptly find competent and experienced successor candidates from our industry-wide network, whom we will nominate for replacement in accordance with the regulatory framework."

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.


The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 65 employees (55 FTEs) at 30 June 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.